AVI BioPharma
Company and Pharmaceutical Company
Exon Skipping Drug Prevents Muscle Wasting And Maintains Muscle Function In Severely Affected, Dystrophin Deficient Mice...therapeutic approach for the treatment of Duchenne muscular dystrophy (DMD). These results were published by researchers at University of Oxford, AVI BioPharma, Inc. (NASDAQ: AVII) and the University of Western Australia, Perth. DMD is an... In this article: AVI Biopharma, University of Oxford, Duchenne muscular dystrophy, Ataxia, Malaria, University of Western Australia, Dystrophin, Medical advice, Dystrophy, and FLU |
-
www.sciencedaily.com
Muscular Dystrophy: Exon Skipping Shows Dramatic Effects In Preventing, Treating Muscle-wasting Disease In Mice
...Neuromuscular and Neurological Disorders, was part of a team which included researchers at The University of Oxford and biotech company AVI BioPharma. The research, published in the journal Molecular Therapy, has demonstrated that a process...
In this article: Muscular dystrophy, Duchenne muscular dystrophy, University of Western Australia, University of Oxford, Cancer, and Utrophin
-
Medical News Today | January 22, 2009
Latest Drug Trial Shows Potential RNA Therapeutic Treatment For Duchenne Muscular Dystrophy, Says Action Duchenne
...a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. The MDEX consortium led...
In this article: Duchenne muscular dystrophy, Muscular dystrophy, Derivative, Newcastle University, and Imperial College London
-
www.avibio.com
Exon Skipping Drug Prevents Muscle Wasting and Maintains ...
AVI BioPharma is focused on the discovery and development of RNA-based drugs ... were published by researchers at University of Oxford, AVI BioPharma, Inc. ...
-
www.evaluatepharma.com
EvaluatePharma - Exon Skipping Drug Prevents Muscle Wasting ...
... were published by researchers at University of Oxford, AVI BioPharma, Inc. ... Oxford University's Medical Sciences Division is one of the largest biomedical ...
-
www.topix.com
AVI BioPharma Wire - Topix
... News Feed for AVI BioPharma. ... by researchers at University of Oxford, AVI BioPharma, Inc. ... at The University of Oxford and biotech company AVI BioPharma. ...
-
www.evri.com
Restenosis, Medical Procedure - News - Evri
AVI BioPharma Pharmaceutical Company. Plavix Heterocyclic Compound. Aspirin Anti ... AVI Biopharma, University of Oxford, Duchenne muscular dystrophy, Oxford, ...
-
www.biospace.com
BioSpace - Print News Article
... In Dystrophin Deficient Mice, University of Oxford Study. 10/20/2009 8: ... were published by researchers at University of Oxford, AVI BioPharma, Inc. ...
-
AVI BioPharma News - Topix
News on AVI BioPharma continually updated from thousands of sources around the net. ... researchers at The University of Oxford and biotech company AVI BioPharma. ...
-
Videos
AVI BioPharma is focused on the discovery and development of RNA-based drugs ... and Genetics, University of Oxford, Oxford, UK; 2AVI Biopharma, Corvallis, ...
Trends
Loading...
More on AVI BioPharma
Description from Wikipedia:
AVI BioPharma Inc. is a medical research and drug development company with corporate offices in Portland, Oregon, United States, and laboratories in Corvallis, Oregon. It was incorporated in 1980. As of 2008, the company has 170 issued medical patents, and over 150 patents pending.
Its primary products are Morpholino oligos (PMOs) first discovered by James Summerton, being developed under the name NeuGene Antisense. This form of antisense therapy uses synthetic RNA to bind to the messenger RNA produced by a known disease-causing gene strand, and thus deactivate it.
Morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty, treatment of coronary artery bypass grafts, treatment of polycystic kidney disease, and redirection of drug metabolism. Morpholinos have been used in preclinical studies to inhibit replication of West Nile Virus, SARS, Hepatitis C, dengue fever, Ebola and Calicivirus, all of which are single stranded RNA viruses. However, clinical studies have not demonstrated significant effects in humans and there are no approved drugs in this class.
In addition to development of Morpholinos as therapeutics, AVI has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine AVICINE.
Explore everything named AVI BioPharma...
